{"id":352078,"date":"2025-08-26T07:08:50","date_gmt":"2025-08-26T07:08:50","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-neurogene\/"},"modified":"2025-08-26T07:08:50","modified_gmt":"2025-08-26T07:08:50","slug":"how-to-buy-neurogene","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/","title":{"rendered":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-352078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Neurogene Inc. (NGNE) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Neurogene Inc. (NGNE) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Gen tedavisi alan\u0131nda yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Neurogene Inc. (NGNE), \u015fu anda biyoteknoloji alan\u0131ndaki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, milyonlarca hayat\u0131 de\u011fi\u015ftirebilecek nadir n\u00f6rolojik hastal\u0131klar i\u00e7in tedaviler geli\u015ftiriyor. NGNE'ye yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi - g\u00fcncel hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine ve neden 2025'in b\u00fcy\u00fcmeye odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in benzersiz f\u0131rsatlar sundu\u011funa kadar - detayl\u0131ca inceleyece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"Gen tedavisi alan\u0131nda yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Neurogene Inc. (NGNE), \u015fu anda biyoteknoloji alan\u0131ndaki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, milyonlarca hayat\u0131 de\u011fi\u015ftirebilecek nadir n\u00f6rolojik hastal\u0131klar i\u00e7in tedaviler geli\u015ftiriyor. NGNE'ye yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi - g\u00fcncel hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine ve neden 2025'in b\u00fcy\u00fcmeye odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in benzersiz f\u0131rsatlar sundu\u011funa kadar - detayl\u0131ca inceleyece\u011fiz."},"body_html":"<h2>\ud83d\udcc8 Neurogene Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>26 A\u011fustos 2025 itibar\u0131yla, Neurogene Inc. (NGNE) NASDAQ'ta <strong>19,75 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Kas\u0131m 2025<\/strong> kesinlikle kritik - Neurogene'nin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu biyoteknoloji kazan\u00e7 raporlar\u0131 fiyatlar\u0131 saatler i\u00e7inde dramatik \u015fekilde hareket ettirebiliyor.<\/p> <p><strong>Klinik Deneme Haberlerinin NGNE Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/strong><\/p> <p>Ger\u00e7ek hareket, geleneksel kazan\u00e7lardan ziyade klinik deneme duyurular\u0131 etraf\u0131nda ger\u00e7ekle\u015fiyor. Neurogene, Haziran 2025'te Rett sendromu gen tedavisi i\u00e7in Embolden\u2122 \u00c7al\u0131\u015fma tasar\u0131m\u0131n\u0131 duyurdu\u011funda (<a href=\"https:\/\/reverserett.org\/news\/articles\/neurogene-embolden-announce-june30-2025\/\">Reverse Rett Foundation<\/a>), hisse senedi yat\u0131r\u0131mc\u0131lar\u0131n etkileri sindirmesiyle \u00f6nemli bir volatilite g\u00f6sterdi.<\/p> <p>Kas\u0131m 2024'\u00fc hat\u0131rl\u0131yor musunuz? O zaman y\u00fcksek doz kohortlar\u0131nda ciddi bir advers olay ya\u015fand\u0131 ve hisse \u00f6n piyasada %34,8 d\u00fc\u015ft\u00fc (<a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/neurogenes-stock-sinks-after-adverse-event-with-rett-syndrome-gene-therapy\/\">Clinical Trials Arena<\/a>). Ancak ilgin\u00e7 olan \u015fu ki - bu aksili\u011fe ra\u011fmen, \u015firket d\u00fc\u015f\u00fck doz kohortundan olumlu veriler geldik\u00e7e toparland\u0131.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Volatilite Analizi<\/h2> <p>Neurogene hisseleri son alt\u0131 ayda tam bir h\u0131z treni yolculu\u011fu ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n neden g\u00fc\u00e7l\u00fc sinirler gerektirdi\u011fini m\u00fckemmel \u015fekilde g\u00f6sterdi:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: Gen tedavisi hatt\u0131 etraf\u0131nda iyimserlik artarken 30-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Nisan-May\u0131s 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 25-28 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc<\/li> <li><strong>Haziran 2025<\/strong>: FDA'n\u0131n kay\u0131t denemesi tasar\u0131m\u0131n\u0131 onaylamas\u0131n\u0131n ard\u0131ndan 40 $ \u00fczeri seviyelere y\u00fckseldi (<a href=\"https:\/\/www.biospace.com\/drug-development\/fda-signs-off-on-neurogenes-best-case-scenario-pivotal-study-design-for-rett-syndrome\/\">BioSpace<\/a>)<\/li> <li><strong>Temmuz-A\u011fustos 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar deneme kay\u0131t g\u00fcncellemelerini beklerken 20 $ civar\u0131nda konsolide oldu<\/li> <\/ul> <p>Neden bu kadar dalgalanma? Neurogene'nin <strong>beta de\u011feri 3,74<\/strong> (<a href=\"https:\/\/marketchameleon.com\/Overview\/NGNE\/Summary\/\">Market Chameleon<\/a>) olup, genel piyasadan neredeyse d\u00f6rt kat daha fazla hareket ediyor. Hissenin 52 haftal\u0131k aral\u0131\u011f\u0131 durumu \u00f6zetliyor: 7,34 $ ile 71,53 $ aras\u0131nda - bu mide buland\u0131r\u0131c\u0131 %875'lik bir fark!<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 25-30 $ aral\u0131\u011f\u0131 (Embolden denemesi i\u00e7in kay\u0131t g\u00fcncellemelerine ba\u011fl\u0131) \u2192 <strong>B\u0130R\u0130KT\u0130R<\/strong><\/li> <li><strong>2026<\/strong>: 35-45 $ (kay\u0131t denemesinden erken klinik veri sonu\u00e7lar\u0131)<\/li> <li><strong>2028<\/strong>: 60-80 $ (potansiyel FDA ba\u015fvurusu ve ortakl\u0131k duyurular\u0131)<\/li> <li><strong>2030<\/strong>: 100 $+ (ticari lansman ba\u015far\u0131s\u0131 ve \u00fcr\u00fcn hatt\u0131 geni\u015flemesi)<\/li> <\/ul> <p>Analistlerin g\u00f6r\u00fc\u015f\u00fc olduk\u00e7a iyimser; <strong>41,86 $ fiyat hedefi<\/strong> %112 y\u00fckseli\u015f potansiyelini temsil ediyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/ngne\/\">StockAnalysis.com<\/a>). Yedi analist hisseyi \"G\u00fc\u00e7l\u00fc Al\" olarak de\u011ferlendiriyor, ancak hedefler 16 $ ile 72 $ aras\u0131nda geni\u015f bir aral\u0131kta - bu da ne kadar belirsizlik oldu\u011funu g\u00f6steriyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Kas\u0131m 2024'teki advers olay, deneysel ila\u00e7lar\u0131n %90'\u0131n\u0131n ba\u015far\u0131s\u0131z oldu\u011funu hat\u0131rlat\u0131yor. Ba\u015fka ciddi bir g\u00fcvenlik sorunu hisseyi \u00e7\u00f6kertebilir.<\/li> <li><strong>Nakit Yakma Krizi<\/strong>: Net zararlar 2025 2. \u00e7eyrekte y\u0131ll\u0131k bazda 18,5 milyon dolardan 22,0 milyon dolara y\u00fckseldi (<a href=\"https:\/\/www.ainvest.com\/news\/neurogene-15-minute-chart-triggers-bollinger-bands-narrowing-kdj-death-cross-detected-2508\/\">AInvest<\/a>). Yak\u0131nda daha fazla finansmana ihtiya\u00e7lar\u0131 olacak.<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA, deneme ortas\u0131nda gereksinimleri de\u011fi\u015ftirebilir, bu da maliyet ve gecikme yarat\u0131r.<\/li> <li><strong>Hisse Seyrelme Riski<\/strong>: Muhtemelen hisse senedi arzlar\u0131 yoluyla sermaye art\u0131rmalar\u0131 gerekecek, bu da mevcut hissedarlar\u0131n pay\u0131n\u0131 seyreltir.<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA Uyum Kazan\u0131m\u0131<\/strong>: Temmuz 2025'te deneme tasar\u0131m\u0131 \u00fczerinde var\u0131lan anla\u015fma analistlere g\u00f6re \"en iyi senaryo\" idi (<a href=\"https:\/\/www.biospace.com\/drug-development\/fda-signs-off-on-neurogenes-best-case-scenario-pivotal-study-design-for-rett-syndrome\/\">BioSpace<\/a>)<\/li> <li><strong>Kar\u015f\u0131lanmam\u0131\u015f T\u0131bbi \u0130htiya\u00e7<\/strong>: Rett sendromu, 10.000 k\u0131z \u00e7ocu\u011fundan 1'ini etkiliyor ve onaylanm\u0131\u015f tedavisi yok - devasa bir pazar f\u0131rsat\u0131<\/li> <li><strong>Patentli Teknoloji<\/strong>: EXACT gen d\u00fczenleme sistemleri, gen tedavisi g\u00fcvenli\u011fi i\u00e7in oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirebilir<\/li> <li><strong>G\u00fc\u00e7l\u00fc Analist Deste\u011fi<\/strong>: 7 analist \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi ve \u00f6nemli y\u00fckseli\u015f hedefleriyle<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 NGNE gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine birka\u00e7 ay boyunca 100-200 $ aras\u0131 al\u0131mlar yap\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Korkun\u00e7 d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 %15-20 stop-loss kullanmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: 2025 4. \u00e7eyrekte Embolden denemesi kay\u0131t g\u00fcncellemelerini izleyin<\/li> <\/ol> <p>Esprili bir yorum: \"NGNE ticareti, g\u00f6zleriniz kapal\u0131 h\u0131z trenine binmek gibi - heyecan verici ama y\u00fckseklik korkunuz oldu\u011funu hat\u0131rlay\u0131nca. Belki \u00f6\u011fle yeme\u011fi paran\u0131z\u0131 g\u00fcvende tutun ve sadece kaybetmeyi g\u00f6ze alabilece\u011finiz kadar bahis yap\u0131n!\"<\/p> <h2>\u2705 Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ hisseleri ve kesirli hisseler sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>K\u00fc\u00e7\u00fck bir miktarla ba\u015flay\u0131n - 50 $ bile ba\u015flang\u0131\u00e7 i\u00e7in yeterlidir<\/td><\/tr> <tr><td>3<\/td><td>NGNE'yi iyice ara\u015ft\u0131r\u0131n<\/td><td>Klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n risklerini anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit emirleri kullan\u0131n<\/td><td>Volatilite art\u0131\u015flar\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc izleyin<\/td><td>NGNE'yi portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle s\u0131n\u0131rlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Neden Uygun?<\/h2> <p>NGNE gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunuyor:<\/p> <ul> <li><strong>Minimum 5 $ depozito<\/strong> - biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek risk do\u011fas\u0131na uygun k\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - fiyat d\u00fc\u015f\u00fc\u015flerinde al\u0131m f\u0131rsatlar\u0131n\u0131 g\u00f6rd\u00fc\u011f\u00fcn\u00fczde h\u0131zl\u0131ca ba\u015flayabilirsiniz<\/li> <li><strong>Kesirli hisseler mevcut<\/strong> - pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 b\u00fcy\u00fck mebla\u011flar taahh\u00fct etmeden sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, tek bir y\u00fcksek riskli hisseye a\u015f\u0131r\u0131 maruz kalmadan \u00e7e\u015fitlendirilmi\u015f bir biyoteknoloji portf\u00f6y\u00fc olu\u015fturmak i\u00e7in idealdir.<\/p> <h2>\ud83e\uddec 2025'te Neurogene: Gen Tedavisi \u00d6nc\u00fcs\u00fc<\/h2> <p>Neurogene, genetik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer al\u0131yor ve y\u0131k\u0131c\u0131 nadir n\u00f6rolojik hastal\u0131klar i\u00e7in tek seferlik tedaviler geli\u015ftiriyor. \u00d6nc\u00fc programlar\u0131 NGN-401, gen\u00e7 k\u0131zlar\u0131n konu\u015fma, y\u00fcr\u00fcme veya ellerini kullanma yetisini kaybetmesine neden olan Rett sendromunu hedefliyor.<\/p> <p>\u015eirketin patentli EXACT teknolojisi, di\u011fer gen tedavisi yakla\u015f\u0131mlar\u0131n\u0131 zorlayan tehlikeli a\u015f\u0131r\u0131 ifade riskini \u00f6nleyerek gen tedavisi g\u00fcvenli\u011finde potansiyel bir at\u0131l\u0131m sunuyor. FDA'n\u0131n kay\u0131t denemesi tasar\u0131m\u0131 \u00fczerindeki onay\u0131 ve yak\u0131nda ba\u015flamas\u0131 beklenen kay\u0131t s\u00fcreci ile 2025 d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir y\u0131l olabilir.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Neurogene'nin Embolden\u2122 denemesi benzersiz bir son nokta kullanacak - hastalar\u0131n hem klinik iyile\u015fme g\u00f6stermesi hem de 28 spesifik beceriden en az bir geli\u015fimsel kilometre ta\u015f\u0131n\u0131 kazanmas\u0131 gerekecek. Bu titiz standart, gen tedavisi onay\u0131 i\u00e7in yeni bir \u00f6l\u00e7\u00fct olu\u015fturabilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Neurogene Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>26 A\u011fustos 2025 itibar\u0131yla, Neurogene Inc. (NGNE) NASDAQ&#8217;ta <strong>19,75 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>Kas\u0131m 2025<\/strong> kesinlikle kritik &#8211; Neurogene&#8217;nin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu biyoteknoloji kazan\u00e7 raporlar\u0131 fiyatlar\u0131 saatler i\u00e7inde dramatik \u015fekilde hareket ettirebiliyor.<\/p>\n<p><strong>Klinik Deneme Haberlerinin NGNE Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/strong><\/p>\n<p>Ger\u00e7ek hareket, geleneksel kazan\u00e7lardan ziyade klinik deneme duyurular\u0131 etraf\u0131nda ger\u00e7ekle\u015fiyor. Neurogene, Haziran 2025&#8217;te Rett sendromu gen tedavisi i\u00e7in Embolden\u2122 \u00c7al\u0131\u015fma tasar\u0131m\u0131n\u0131 duyurdu\u011funda (<a href=\"https:\/\/reverserett.org\/news\/articles\/neurogene-embolden-announce-june30-2025\/\">Reverse Rett Foundation<\/a>), hisse senedi yat\u0131r\u0131mc\u0131lar\u0131n etkileri sindirmesiyle \u00f6nemli bir volatilite g\u00f6sterdi.<\/p>\n<p>Kas\u0131m 2024&#8217;\u00fc hat\u0131rl\u0131yor musunuz? O zaman y\u00fcksek doz kohortlar\u0131nda ciddi bir advers olay ya\u015fand\u0131 ve hisse \u00f6n piyasada %34,8 d\u00fc\u015ft\u00fc (<a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/neurogenes-stock-sinks-after-adverse-event-with-rett-syndrome-gene-therapy\/\">Clinical Trials Arena<\/a>). Ancak ilgin\u00e7 olan \u015fu ki &#8211; bu aksili\u011fe ra\u011fmen, \u015firket d\u00fc\u015f\u00fck doz kohortundan olumlu veriler geldik\u00e7e toparland\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Volatilite Analizi<\/h2>\n<p>Neurogene hisseleri son alt\u0131 ayda tam bir h\u0131z treni yolculu\u011fu ya\u015fad\u0131 ve biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n neden g\u00fc\u00e7l\u00fc sinirler gerektirdi\u011fini m\u00fckemmel \u015fekilde g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: Gen tedavisi hatt\u0131 etraf\u0131nda iyimserlik artarken 30-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Nisan-May\u0131s 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 25-28 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc<\/li>\n<li><strong>Haziran 2025<\/strong>: FDA&#8217;n\u0131n kay\u0131t denemesi tasar\u0131m\u0131n\u0131 onaylamas\u0131n\u0131n ard\u0131ndan 40 $ \u00fczeri seviyelere y\u00fckseldi (<a href=\"https:\/\/www.biospace.com\/drug-development\/fda-signs-off-on-neurogenes-best-case-scenario-pivotal-study-design-for-rett-syndrome\/\">BioSpace<\/a>)<\/li>\n<li><strong>Temmuz-A\u011fustos 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar deneme kay\u0131t g\u00fcncellemelerini beklerken 20 $ civar\u0131nda konsolide oldu<\/li>\n<\/ul>\n<p>Neden bu kadar dalgalanma? Neurogene&#8217;nin <strong>beta de\u011feri 3,74<\/strong> (<a href=\"https:\/\/marketchameleon.com\/Overview\/NGNE\/Summary\/\">Market Chameleon<\/a>) olup, genel piyasadan neredeyse d\u00f6rt kat daha fazla hareket ediyor. Hissenin 52 haftal\u0131k aral\u0131\u011f\u0131 durumu \u00f6zetliyor: 7,34 $ ile 71,53 $ aras\u0131nda &#8211; bu mide buland\u0131r\u0131c\u0131 %875&#8217;lik bir fark!<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 25-30 $ aral\u0131\u011f\u0131 (Embolden denemesi i\u00e7in kay\u0131t g\u00fcncellemelerine ba\u011fl\u0131) \u2192 <strong>B\u0130R\u0130KT\u0130R<\/strong><\/li>\n<li><strong>2026<\/strong>: 35-45 $ (kay\u0131t denemesinden erken klinik veri sonu\u00e7lar\u0131)<\/li>\n<li><strong>2028<\/strong>: 60-80 $ (potansiyel FDA ba\u015fvurusu ve ortakl\u0131k duyurular\u0131)<\/li>\n<li><strong>2030<\/strong>: 100 $+ (ticari lansman ba\u015far\u0131s\u0131 ve \u00fcr\u00fcn hatt\u0131 geni\u015flemesi)<\/li>\n<\/ul>\n<p>Analistlerin g\u00f6r\u00fc\u015f\u00fc olduk\u00e7a iyimser; <strong>41,86 $ fiyat hedefi<\/strong> %112 y\u00fckseli\u015f potansiyelini temsil ediyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/ngne\/\">StockAnalysis.com<\/a>). Yedi analist hisseyi &#8220;G\u00fc\u00e7l\u00fc Al&#8221; olarak de\u011ferlendiriyor, ancak hedefler 16 $ ile 72 $ aras\u0131nda geni\u015f bir aral\u0131kta &#8211; bu da ne kadar belirsizlik oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Kas\u0131m 2024&#8217;teki advers olay, deneysel ila\u00e7lar\u0131n %90&#8217;\u0131n\u0131n ba\u015far\u0131s\u0131z oldu\u011funu hat\u0131rlat\u0131yor. Ba\u015fka ciddi bir g\u00fcvenlik sorunu hisseyi \u00e7\u00f6kertebilir.<\/li>\n<li><strong>Nakit Yakma Krizi<\/strong>: Net zararlar 2025 2. \u00e7eyrekte y\u0131ll\u0131k bazda 18,5 milyon dolardan 22,0 milyon dolara y\u00fckseldi (<a href=\"https:\/\/www.ainvest.com\/news\/neurogene-15-minute-chart-triggers-bollinger-bands-narrowing-kdj-death-cross-detected-2508\/\">AInvest<\/a>). Yak\u0131nda daha fazla finansmana ihtiya\u00e7lar\u0131 olacak.<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA, deneme ortas\u0131nda gereksinimleri de\u011fi\u015ftirebilir, bu da maliyet ve gecikme yarat\u0131r.<\/li>\n<li><strong>Hisse Seyrelme Riski<\/strong>: Muhtemelen hisse senedi arzlar\u0131 yoluyla sermaye art\u0131rmalar\u0131 gerekecek, bu da mevcut hissedarlar\u0131n pay\u0131n\u0131 seyreltir.<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA Uyum Kazan\u0131m\u0131<\/strong>: Temmuz 2025&#8217;te deneme tasar\u0131m\u0131 \u00fczerinde var\u0131lan anla\u015fma analistlere g\u00f6re &#8220;en iyi senaryo&#8221; idi (<a href=\"https:\/\/www.biospace.com\/drug-development\/fda-signs-off-on-neurogenes-best-case-scenario-pivotal-study-design-for-rett-syndrome\/\">BioSpace<\/a>)<\/li>\n<li><strong>Kar\u015f\u0131lanmam\u0131\u015f T\u0131bbi \u0130htiya\u00e7<\/strong>: Rett sendromu, 10.000 k\u0131z \u00e7ocu\u011fundan 1&#8217;ini etkiliyor ve onaylanm\u0131\u015f tedavisi yok &#8211; devasa bir pazar f\u0131rsat\u0131<\/li>\n<li><strong>Patentli Teknoloji<\/strong>: EXACT gen d\u00fczenleme sistemleri, gen tedavisi g\u00fcvenli\u011fi i\u00e7in oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirebilir<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Analist Deste\u011fi<\/strong>: 7 analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi ve \u00f6nemli y\u00fckseli\u015f hedefleriyle<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 NGNE gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine birka\u00e7 ay boyunca 100-200 $ aras\u0131 al\u0131mlar yap\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Korkun\u00e7 d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 %15-20 stop-loss kullanmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Kataliz\u00f6rleri Takip Edin<\/strong>: 2025 4. \u00e7eyrekte Embolden denemesi kay\u0131t g\u00fcncellemelerini izleyin<\/li>\n<\/ol>\n<p>Esprili bir yorum: &#8220;NGNE ticareti, g\u00f6zleriniz kapal\u0131 h\u0131z trenine binmek gibi &#8211; heyecan verici ama y\u00fckseklik korkunuz oldu\u011funu hat\u0131rlay\u0131nca. Belki \u00f6\u011fle yeme\u011fi paran\u0131z\u0131 g\u00fcvende tutun ve sadece kaybetmeyi g\u00f6ze alabilece\u011finiz kadar bahis yap\u0131n!&#8221;<\/p>\n<h2>\u2705 Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ hisseleri ve kesirli hisseler sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>K\u00fc\u00e7\u00fck bir miktarla ba\u015flay\u0131n &#8211; 50 $ bile ba\u015flang\u0131\u00e7 i\u00e7in yeterlidir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>NGNE&#8217;yi iyice ara\u015ft\u0131r\u0131n<\/td>\n<td>Klinik a\u015famadaki biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emirleri kullan\u0131n<\/td>\n<td>Volatilite art\u0131\u015flar\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc izleyin<\/td>\n<td>NGNE&#8217;yi portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle s\u0131n\u0131rlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Neden Uygun?<\/h2>\n<p>NGNE gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunuyor:<\/p>\n<ul>\n<li><strong>Minimum 5 $ depozito<\/strong> &#8211; biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek risk do\u011fas\u0131na uygun k\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; fiyat d\u00fc\u015f\u00fc\u015flerinde al\u0131m f\u0131rsatlar\u0131n\u0131 g\u00f6rd\u00fc\u011f\u00fcn\u00fczde h\u0131zl\u0131ca ba\u015flayabilirsiniz<\/li>\n<li><strong>Kesirli hisseler mevcut<\/strong> &#8211; pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 b\u00fcy\u00fck mebla\u011flar taahh\u00fct etmeden sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, tek bir y\u00fcksek riskli hisseye a\u015f\u0131r\u0131 maruz kalmadan \u00e7e\u015fitlendirilmi\u015f bir biyoteknoloji portf\u00f6y\u00fc olu\u015fturmak i\u00e7in idealdir.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te Neurogene: Gen Tedavisi \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Neurogene, genetik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer al\u0131yor ve y\u0131k\u0131c\u0131 nadir n\u00f6rolojik hastal\u0131klar i\u00e7in tek seferlik tedaviler geli\u015ftiriyor. \u00d6nc\u00fc programlar\u0131 NGN-401, gen\u00e7 k\u0131zlar\u0131n konu\u015fma, y\u00fcr\u00fcme veya ellerini kullanma yetisini kaybetmesine neden olan Rett sendromunu hedefliyor.<\/p>\n<p>\u015eirketin patentli EXACT teknolojisi, di\u011fer gen tedavisi yakla\u015f\u0131mlar\u0131n\u0131 zorlayan tehlikeli a\u015f\u0131r\u0131 ifade riskini \u00f6nleyerek gen tedavisi g\u00fcvenli\u011finde potansiyel bir at\u0131l\u0131m sunuyor. FDA&#8217;n\u0131n kay\u0131t denemesi tasar\u0131m\u0131 \u00fczerindeki onay\u0131 ve yak\u0131nda ba\u015flamas\u0131 beklenen kay\u0131t s\u00fcreci ile 2025 d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir y\u0131l olabilir.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Neurogene&#8217;nin Embolden\u2122 denemesi benzersiz bir son nokta kullanacak &#8211; hastalar\u0131n hem klinik iyile\u015fme g\u00f6stermesi hem de 28 spesifik beceriden en az bir geli\u015fimsel kilometre ta\u015f\u0131n\u0131 kazanmas\u0131 gerekecek. Bu titiz standart, gen tedavisi onay\u0131 i\u00e7in yeni bir \u00f6l\u00e7\u00fct olu\u015fturabilir!<\/p>\n"},"faq":[{"question":"Neurogene Inc. (NGNE) hisseleri nereden al\u0131nabilir?","answer":"NGNE hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"NGNE hisseleri ne kadar risklidir?","answer":"NGNE, beta de\u011feri 3,74 olan y\u00fcksek volatiliteye sahip bir biyoteknoloji hissesi oldu\u011fundan y\u00fcksek risk ta\u015f\u0131r. Klinik deneme sonu\u00e7lar\u0131 ve reg\u00fclasyon haberleri fiyatlar\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir."},{"question":"2025 i\u00e7in NGNE hisse fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 41,86 $ olup, 2025 y\u0131l sonu i\u00e7in 25-30 $ aral\u0131\u011f\u0131nda bir fiyat beklenmektedir."},{"question":"Yeni ba\u015flayan biri NGNE hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, stop-loss kullanmak ve klinik deneme g\u00fcncellemelerini takip etmek ak\u0131ll\u0131ca olacakt\u0131r."},{"question":"Pocket Option NGNE hisseleri i\u00e7in neden tercih edilebilir?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve kesirli hisse al\u0131m imkan\u0131 sunarak yeni biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygun bir platformdur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Neurogene Inc. (NGNE) hisseleri nereden al\u0131nabilir?","answer":"NGNE hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"NGNE hisseleri ne kadar risklidir?","answer":"NGNE, beta de\u011feri 3,74 olan y\u00fcksek volatiliteye sahip bir biyoteknoloji hissesi oldu\u011fundan y\u00fcksek risk ta\u015f\u0131r. Klinik deneme sonu\u00e7lar\u0131 ve reg\u00fclasyon haberleri fiyatlar\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir."},{"question":"2025 i\u00e7in NGNE hisse fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 41,86 $ olup, 2025 y\u0131l sonu i\u00e7in 25-30 $ aral\u0131\u011f\u0131nda bir fiyat beklenmektedir."},{"question":"Yeni ba\u015flayan biri NGNE hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, stop-loss kullanmak ve klinik deneme g\u00fcncellemelerini takip etmek ak\u0131ll\u0131ca olacakt\u0131r."},{"question":"Pocket Option NGNE hisseleri i\u00e7in neden tercih edilebilir?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve kesirli hisse al\u0131m imkan\u0131 sunarak yeni biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygun bir platformdur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:08:50+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T07:08:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\",\"name\":\"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-26T07:08:50+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/","og_locale":"tr_TR","og_type":"article","og_title":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T07:08:50+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T07:08:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/","name":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-26T07:08:50+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-neurogene\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Neurogene Inc. (NGNE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Neurogene Inc. (NGNE) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":352079,"slug":"how-to-buy-neurogene","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Neurogene Inc. (NGNE) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Neurogene Inc. (NGNE)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-neurogene\/"},"pt_AA":{"locale":"pt_AA","id":352077,"slug":"how-to-buy-neurogene","post_title":"Como comprar a\u00e7\u00f5es da Neurogene Inc. (NGNE) - Investimento em a\u00e7\u00f5es da Neurogene Inc. (NGNE)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-neurogene\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=352078"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352078\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=352078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=352078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=352078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}